Shaalan Beg: Modernizing evidence generation for regulatory approvals at ASCOBT24
Shaalan Beg, Senior Advisor for Clinical Research at the Vivek Subbiah on X:
“Look forward to talking about modernizing evidence generation for regulatory approvals at ASCOBT24.”
Quoting Vivek Subbiah’s post:
“Modernize Precision Oncology With Decentralized Trial Tools.”
Source: Shaalan Beg/X and Vivek Subbiah/X
Authors: Muhammad Shaalan Beg,Vivek Subbiah
Modernize Precision Oncology With Decentralized Trial Tools
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer.
He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023